Pain Control in Colorectal Surgery: Liposomal Bupivacaine Block Versus Intravenous Lidociane

PHASE4CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

February 22, 2018

Primary Completion Date

May 9, 2019

Study Completion Date

July 20, 2021

Conditions
Colorectal Disorders
Interventions
DRUG

Exparel

"2\. Liposomal bupivacaine TAP block (experimental arm)~1. Block will be administered after induction of anesthesia and before incision by a specifically trained attending surgeon or surgical fellow with the colorectal service.~2. A single vial of liposomal bupivacaine (20 mL 1.3%, 13.3mg/mL, 266 mg) will be diluted in 50cc bupivacaine to a volume of 60cc prior to administration. This will be divided into 2 doses for bilateral TAP blocks.~3. The LB will be administered under ultrasound guidance in the transversus abdominis plain per manufacturer recommendations.~4. Adhesive tapes will be applied at the level of the TAP block puncture sites."

DRUG

IV Lidocaine

"1\. Intravenous Lidocaine infusion (control arm, current standard of care)~1. 100 mg/5mL intravenous bolus of lidocaine 2% PF 5mL will be initiated by anesthesia service prior to general anesthesia induction.~2. 1.5 mg/kg/hr to begin prior to incision and continue until discontinued 1 hr postoperatively in PACU. Patients will be monitored in PACU for at least 30 minutes after discontinuation of lidocaine drip.~3. Adhesive tapes will be applied at the presumed level of TAP block puncture sites."

Trial Locations (1)

28204

Atrium Health - Carolinas Medical Center, Charlotte

All Listed Sponsors
lead

Wake Forest University Health Sciences

OTHER

NCT04005859 - Pain Control in Colorectal Surgery: Liposomal Bupivacaine Block Versus Intravenous Lidociane | Biotech Hunter | Biotech Hunter